

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number
WO 03/093322 A2(51) International Patent Classification⁷: C08B

[US/US]; 523 Midwood Drive, Brick, NJ 08724-4727 (US). BUBNIS, William, A. [US/US]; 9088 Kings Charter Drive, Mechanicsville, VA 23116 (US).

(21) International Application Number: PCT/US03/13456

(22) International Filing Date: 30 April 2003 (30.04.2003)

(74) Agents: FOLEY, Shawn, P.; Lerner, David, Littenberg, Krumholz & Mentlik, LLP, 600 South Avenue West, Westfield, NJ 07090 et al. (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/376,400 30 April 2002 (30.04.2002) US
60/377,050 1 May 2002 (01.05.2002) US(81) Designated States (*national*): AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.(71) Applicants (*for all designated States except US*): THE POPULATION COUNCIL, INC. [US/US]; One Dag Hammarskjold Plaza, New York, NY 10017 (US). FMC CORPORATION [US/US]; 1735 Market Street, Philadelphia, PA 19103 (US).(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and



(75) Inventors/Applicants (*for US only*): MAGUIRE, Robin, A. [US/US]; 33 1/2 Terrace Avenue, Ossining, NY 10562 (US). THORN, Mitchell [US/US]; 1914 24th Road, Astoria, NY 11102-3449 (US). PHILLIPS, David, M. [US/US]; 10 Ladik Street, Piermont, NY 10968 (US). BLAKEMORE, William, R. [GB/US]; 13 Garnet Drive, Topsham, ME 04086 (US). BALLARD, Arthur, D. [US/US]; 26 Palm Road, Westport, MN 04578 (US). SEWALL, Christopher, J. [US/US]; 15 Jones Hill Road, Hope, MN 04847 (US). MODLISZEWSKI, James, J.

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ENHANCED SULFATED POLYSACCHARIDE FORMULATIONS, METHODS AND PREPARATIONS AND THEIR USES THEREOF

Blocking of HIV-1TM infection of PBMCs. Zn-carrageenan and LSA-carrageenan are efficacious at lower concentration than Carrageenan

(57) Abstract: Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contains one or more carrageenans, including lambda carrageenan. Also disclosed are methods for making and using the compositions.

ENHANCED SULFATED POLYSACCHARIDE FORMULATIONS, METHODS OF PREPARATIONS AND THEIR USES THEREOF

5 BACKGROUND OF THE INVENTION

Carrageenans are polysaccharides obtained from the red algae commonly known as seaweed. They are a structural component of seaweed and are extracted as three main types, namely iota, kappa and lambda, although there are other types as well, including kappa-II, mu and nu carrageenans. Carrageenans have been used extensively in the food, pharmaceutical and cosmetics industries as thickeners, gelling agent, and stabilizing and dispersing agents. Extensive pharmacological and toxicological studies have been conducted. Carrageenan has been found to be non-toxic by oral, dermal, and inhalation routes of administrations even at extremely high doses. The carrageenans were therefore classified as "generally recognized as safe" (GRAS) by the FDA in 1972². Further extensive oral pharmacokinetic studies conducted in pigs, rats, mice, gerbils, guinea pigs, ferrets, hamsters, dogs, and monkeys³⁻¹¹ showed that the breakdown of the carrageenans in the gastrointestinal tract were minimal at best and that absorption was virtually non-existent

International Patent Publication WO 94/15624 teaches use of sulfated polysaccharides such as iota carrageenan, dextran sulfate, kappa carrageenan, lambda carrageenan, heparin mimetics, heparin sulfate, pentosan polysulfate, chondroitin sulfate, lentinan sulfate, curdlan sulfate, de-N-sulfated heparin and fucoidan, to inhibit cell-to-cell transmission of HIV and thus the sexual transmission of Acquired Immune Deficiency Syndrome (AIDS), as well as *Chlamydia* organism. This publication teaches that iota carrageenan is the most efficacious of the commercially available sulfated carrageenans in preventing HIV infection and in blocking *Chlamydia* infection *in vitro* and *in vivo*.

SUMMARY OF THE INVENTION

Applicants have discovered that a certain carrageenan or mixtures or combinations of various carrageenans possess specific physical and chemical properties and that when they are formulated for vaginal administration, they provide a prolonged antimicrobial effect and inhibit or reduce the possibility of transmission of a sexually transmitted infection (STI).

Accordingly, a first aspect of the present invention is directed to an aqueous antimicrobial composition, comprising an effective amount of an antimicrobial agent

comprising carrageenans (referred to herein as "the carrageenans" or a "carrageenan mixture") which are lambda carrageenan in an amount of at least about 50% by dry weight of said carrageenans, remainder of said carrageenans being at least one non-lambda carrageenan, and a physiologically acceptable pH controlling agent. For purposes of the present invention,
5 the term "antimicrobial" is meant to embrace anti-bacterial and/or antiviral activity.

A related aspect of the present invention is directed to a sexually transmitted infection (STI) inhibiting composition, comprising an effective amount of an antimicrobial agent comprising carrageenans which are lambda carrageenan in an amount of at least about 50% by dry weight of said carrageenans, remainder of said carrageenans being at least one non-
10 lambda carrageenan, and a physiologically acceptable pH controlling agent.

The compositions may further include another antimicrobial agent and/or a vaginally administerable drug, in which case the carrageenan component may be a lambda carrageenan, without any non-lambda carrageenan. The additional agent may be in admixture and/or associated with the carrageenans such as in the form of a complex. Accordingly, a further
15 aspect of the present invention is directed to aqueous antimicrobial composition, comprising: (a) a physiologically acceptable pH controlling agent; and (b) an effective amount of an antimicrobial agent comprising a complex of a lambda carrageenan or carrageenans which are lambda carrageenan in an amount of at least about 50% by dry weight of said carrageenans, remainder of said carrageenans being at least one non-lambda carrageenan, and
20 an antimicrobial, physiologically acceptable water-soluble cationic metal salt.

A further aspect of the present invention is directed to an aqueous antimicrobial composition, comprising: (a) a physiologically acceptable pH controlling agent; (b) an effective amount of an antimicrobial agent comprising a complex of a lambda carrageenan or carrageenans which are lambda carrageenan in an amount of at least about 50% by dry
25 weight of said carrageenans, remainder of said carrageenans being at least one non-lambda carrageenan; and (c) a lignosulfonic acid.

A further aspect of the present invention is directed to an aqueous antimicrobial composition, comprising: (a) a physiologically acceptable pH controlling agent; (b) an effective amount of an antimicrobial agent comprising a complex of a lambda carrageenan or
30 carrageenans which are lambda carrageenan in an amount of at least about 50% by dry weight of said carrageenans, remainder of said carrageenans being at least one non-lambda

carrageenan; and (c) a vaginally administrable drug such as a contraceptive agent or an agent for hormone replacement therapy.

A further aspect of the present invention is directed to a method of processing, refining or stabilizing the carrageenans of the present invention. The method entails mixing a
5 lambda carrageenan or the carrageenans in anhydrous or powdery form with the dry form of the pHcontrolling agent, followed by hydration of the carrageenans e.g., by the addition of water or another aqueous solution. The method overcomes several disadvantages associated with current techniques for processing high concentrations of carrageenans into homogenous aqueous solutions and facilitates further processing into pharmaceutical formulations such as
10 the aforementioned compositions and complexes.

DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph showing long-term activity of a composition containing the carrageenans of the present invention. Mice were challenged with a 95-100% infectious dose of HSV-2 at various time intervals after application of the composition. The composition
15 retains some level of activity against HSV-2 even after 24 hours. This suggests that a woman could be protected even if considerable time elapsed between use of the composition and coitus.

Fig. 2 is a graph of Southern Blot hybridization of RT PCR products from RNA extracted from the spleens. Lane 2 and 3 are positive controls. Lanes 4 to 8 are from mice that
20 were pretreated with a composition containing the carrageenans of the present invention, 5 minutes before viral challenge. Lanes 9 to 14 are from mice inoculated vaginally with HIV.

Fig. 3 is a bar graph showing p24 (HIV) concentration versus concentration of a composition containing the carrageenans of the present invention, another composition of the present invention that contains a complex of the carrageenans and a water-soluble zinc salt
25 ("zinc-carrageenan"), and lignosulfonic acid (LSA).

Fig. 4 is a graph showing comparison between a composition of the present invention containing the carrageenans and LSA, and a composition of the present invention containing the carrageenans, in the HSV-2/Mouse system. The results show that the composition containing LSA and the carrageenans is more efficacious than a composition containing the
30 carrageenans alone.

Fig. 5 is a plot of the percent inhibition by LSA of viral replication as measured by

p24 ELISA.

Fig. 6 is a graph of the efficacy of a composition containing the carrageenans of the present invention, and another composition of the present invention that contains zinc-carrageenan, in preventing plaque formation of HSV-2 in Vero cells as a function of dose.

5 Fig. 7 is a graph showing the efficacy of a composition containing the carrageenans of the present invention, and another composition of the present invention that contains zinc-carrageenan, in protecting mice from infection from HSV-2, following vaginal challenge.

Fig. 8 is a graph showing the comparison of long-term activity of a composition of the present invention containing zinc-carrageenan compared to two known products, Conceptrol and Advantage S, at a viral challenge dose of 10^4 or 100% infection dose of HSV-2.

10 Fig. 9 is a graph showing protection against viral challenge by a composition containing the carrageenans of the present invention, and another composition of the present invention that contains zinc-carrageenan.

Fig. 10 is a graph of the amount of Nestorone released from a composition containing the carrageenans of the present invention.

15 Fig. 11 is a bar graph comparing the effectiveness of various dilutions of carrageenan compositions of the present invention in protecting mice from infection by HSV-2. Results show that even when the carrageenans are diluted 1:200, they still were able to provide 40% protection from infection.

20 DETAILED DESCRIPTION OF THE INVENTION

The carrageenans present in compositions of the present invention include a lambda carrageenan. To the extent that non-lambda carrageenans are present (in which the case the carrageenan component of the compositions may be referred to as "the carrageenans" or the "carrageenans mixture"), the carrageenans mixture contains at least about 50% (and preferably at least 50%) of lambda carrageenan, based on total dry weight of the carrageenans in the composition. In more preferred embodiments, the amount of lambda carrageenan is at least about 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 % of the total dry weight of the carrageenans (i.e., lambda and non-lambda carrageenans). Other preferred amounts are at least 75%, at least about 85%, at least about 95%, about 85 to about 99%, and from about 94 to about 97% lambda carrageenan.

Lambda carrageenan is commercially available (FMC Corp., Philadelphia). Alternatively, lambda carrageenan can be produced from diploid (sporophyte) seaweed plants e.g., *Gigartina radula*, *Gigartina skottsbergii*, *Gigartina chamissoi*, *Gigartina stellata*, *Iridaea cordata*, *Chondrus crispus* and *Sarcothalia crispata*. Isolation of the carrageenan from the seaweed is conducted in accordance with standard techniques. For example, the seaweed is separated, cleaned and then dried. Lambda carrageenan is extracted in hot dilute sodium hydroxide, yielding a paste that contains as much as 4% concentration of lambda carrageenan. The resulting paste is clarified by centrifugation and filtration to yield a clear, lambda carrageenan solution. Water is removed by any combination of evaporation, alcohol precipitation or washing, and drying.

The remainder of the carrageenans in compositions of the present invention may include at least one non-lambda carrageenan. By "non-lambda carrageenan", it is meant any carrageenan other than *lambda* carrageenan, such as *kappa*-carrageenan, *iota* carrageenan, *kappa-II* carrageenan (which contains *kappa* and *iota* carrageenans), *mu* carrageenan, and *nu* carrageenan. Non-*lambda* carrageenans are also available commercially (e.g., FMC Corp.) or may be extracted from seaweed in accordance with standard techniques. For example, *kappa-II* carrageenan is also naturally present in the species of seaweed described above. In preferred embodiments, the non-lambda carrageenans include *kappa* carrageenan, *iota* carrageenan, and *kappa-II* carrageenans, and mixtures of any two or more thereof. In more preferred embodiments, the non-lambda carrageenan includes *kappa-II* carrageenan. In preferred embodiments, the non-lambda component of the carrageenans constitutes less than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or about 25% of the total dry weight of the carrageenans. In more preferred embodiments, the non-lambda component is about less than about 25 %, less than about 15%, less than about 5 %, about 1 to about 15%, or about 3 to about 6% of the total dry weight of the carrageenans. In other preferred embodiments, the carrageenan mixture is substantially or entirely free of dextrose, an ingredient commonly found in carrageenans used in the food industry.

In order to provide an antimicrobial effect, the lambda carrageenan or the carrageenans are generally present in amounts of about 1 to about 5%, based on total weight of the composition. In preferred embodiments, the carrageenans are present in amount of about 3% by total weight of the composition. By "antimicrobial" or "antimicrobial effect", it

is meant that the composition inhibits or reduces the likelihood of transmission of a sexually transmitted infection caused by a bacterium, another microbe or a virus. The compositions of the present invention useful in protection against sexually transmitted infections e.g., by inhibiting infection by HIV, HPV, HSV-2 and *Neisseria gonorrhoeae*. On the other hand, the terms “antimicrobial” and “antimicrobial effect” are not meant to convey, imply or be limited to any particular means by which the inhibition of transmission of the infection is accomplished. Without intending to be bound by any particular theory of operation, it is believed that the carrageenans non-specifically bind to virus, bacteria and other microbes that are etiological agents of STIs, thereby blocking receptor sites. Compositions containing the lambda carrageenan or the carrageenans in amounts less than 1% or greater than 5% may be used, so long as that they provide an antimicrobial effect and retain vaginal acceptability. By “vaginal acceptability”, it is meant that the rheological properties such as viscosity of composition allow it to be used for its intended purpose (e.g., the composition maintains a viscosity so that it can be applied by the user and be retained in the vaginal vault, as well as providing aesthetic properties such as being substantially odorless, smoothness, clarity, colorlessness and tastelessness). The viscosity is selected so as to enable the composition to evenly coat the epithelial lining of the vaginal vault. In general, the viscosity of the compositions is about 10,000 to about 50,000 cP, preferably about 20,000 to about 50,000 cP, and more preferably about 30,000 to about 35,000 cP. Carrageenan has a continuum of molecular weights. In general, the carrageenan mixtures of the present invention may have a molecular weight of up to about 2×10^6 daltons with less than about 1% of carrageenan molecules having an average molecular weight of 1×10^5 daltons (as determined by gas permeation chromatography and light scattering). More particularly, a lambda carrageenan in the invention has a weight average molecular weight of about 600,000 to about 1,200,000 daltons. This physical property imparts non-absorbability to the final formulation that in turn provides prolonged anti-microbial activity.

The composition further contains a physiologically acceptable pH controlling agent such as phosphate buffered saline (PBS). In addition to stabilizing the pH of the composition (e.g., at a level of about 3.5 to about 8.5, and preferably about 6.8 to about 7.2), the pH controlling agent prevents or reduces any change of the change in the composition once it is introduced into the body where the pH can vary significantly. Vaginal pH can range between

3.5 to 5.5. Thus, the presence of the pH controlling agent extends the antimicrobial effect of the carrageenans. The compositions formulation may further contain other active agents and/or inert ingredients, depending upon the intended use (as described below).

The carrageenans of the present invention provide several other benefits. They remain stable if exposed to freezing, ambient, or boiling temperatures. The mixture is compatible with the human vaginal environment. Without intending to be bound by any particular theory of operation, it is believed that the carrageenans are compatible with the human vaginal environment and do not act as a substrate or otherwise cause or stimulate growth of natural vaginal flora, nor are they toxic so as to disrupt the natural floral balance in the vagina. Aside from the properties attributable to the carrageenans of the present invention, their antimicrobial activity extends over a period of time because they are not systemically absorbed or degraded to any absorbable by-products detrimental to humans.

Another aspect of the present invention is directed to a complex between a water-insoluble metal salt and the carrageenans. In preferred embodiments, the metal salt is a zinc salt (and the antimicrobial composition is referred to as "zinc carrageenate". Zinc is an inhibitor of such sexually transmitted pathogens as HIV and HSV-2. Zinc acetate and zinc sulfate have been shown to inhibit HIV infection in cell culture, and HSV-2 in both cell culture and laboratory animals. Zinc salts have been shown to be effective in blocking infection by HIV *in vitro*³⁹, foot-and-mouth virus, human rhinovirus, influenza A and B, semliki forest virus and sindbis virus⁴⁰. Haraguchi, et al.³⁹ found that zinc chloride, cadmium acetate and mercury chloride inhibited HIV-1 production as assayed by p24 ELISA and RT. Zinc chloride did not exhibit significant cytotoxicity when present in concentrations of up to 550 µg/mL.

Water-soluble zinc salts useful in the present invention include both inorganic salts and organic salts that exhibit anti-microbial properties without causing unacceptable irritation when used in accordance with the present invention. Preferred water-soluble zinc salts include zinc acetate, zinc propionate, zinc butyrate, zinc formate, zinc gluconate, zinc glycerate, zinc glycolate, zinc lactate, zinc sulfate, zinc chloride, and zinc bromide. ZnSO₄, ZnCl₂, ZnBr₂, Zn(Ac)₂, etc. Copper and silver counterpart salts are also useful in the present invention provided that they are non-irritating *in vivo* and do not cause degradation to any absorbable by-products detrimental to humans. The anti-microbial activity of the

composition is greater than a formulation containing the carrageenans as the only anti-microbial agent. In embodiments of the present invention with specific zinc salts, there is a significant increase in anti-microbial activity. Without intended to be bound by any particular theory of operation, it is believed that the anti-microbial activity of the formulation is enhanced because the rate at which the metal salt is absorbed by the body is relatively controlled and at the same time, the irritation of the metal salt is reduced.

The complexes of the present invention may be prepared by standard processes whereby the metal ions replace cations that are naturally present on the backbone of the polysaccharide. For example, zinc carrageenan (which refers to a complex between zinc cations and the carrageenans of the present invention) is a compound synthesized by a procedure whereby zinc (II) is non-covalently attached to the sulfate groups of the carrageenans. Carrageenan is a polysaccharide consisting of repeating D-galactose and 3,6-anhydro D-galactose units arranged in a linear fashion. The polymer is highly sulfated having 3 SO_3 groups per each disaccharide unit. The binding of zinc to the carrageenans is accomplished by a chemical process developed to replace sodium bound to native carrageenan with zinc. An aqueous solution of a highly soluble zinc salt (such as zinc acetate) is used in this process as a source of zinc cations. The carrageenans are dialyzed against a concentrated solution of zinc acetate allowing positively charged zinc ions to diffuse and complex with the negative sulfate groups of the carrageenans. Excess of zinc is then removed by dialysis against water.

The inclusion of a complex of zinc II metal cations with the carrageenans in the present invention can be achieved by the use of zinc II carrageenate. Zinc carrageenate is synthesized by substitution of the natural carrageenan cations (sodium, potassium, calcium) by zinc cations. Zinc carrageenate is traditionally prepared by dialysis of a solution of carrageenan against a concentrated solution of zinc II acetate. Excess zinc cations are then removed by dialysis against water, before concentrating, and for example, freeze drying. The use of zinc II carrageenate can avoid the use of anions such as lactate or acetate in the present invention.

Another process entails (a) soaking the carrageenans in about a 2.5% zinc lactate (or other suitable soluble zinc salt) in 50:50 alcohol:water liquor for two hours, (b) separated, and (c) washed with alcohol before drying. Steps (a) through (c) may need to be repeated several

times to achieve the desired metal content in the carrageenans. Two cycles are normally required to achieve over 50% zinc carrageenan on an equivalent basis.

The above procedures generate a compound, which is water soluble and active against enveloped viruses such as HIV and HSV-2. Unlike inorganic or simple organic zinc salts, zinc carrageenan maintains the preferred rheological properties and possesses a high molecular weight (up to 2,000,000 Da) making it amenable to be formulated into a vaginal product, which is non-irritating and not absorbed. The composition is referred to as a "complex" due to the presence of molecular interactions between the metal and the carrageenans that disfavor or discourage its dissociation to free metal cations. The present complexes of a metal salt and a negatively charged sulfated-polysaccharide complex are distinct from mixtures of water-soluble metal salts and carrageenans in terms of their physical, chemical and/or anti-microbial properties

In another aspect of the present invention, lignosulfonic acid ("LSA") is combined with a lambda carrageenan or the carrageenans (referred to herein as LSA-carrageenan), to achieve an enhanced anti-microbial effect. LSA is commercially used as an industrial stabilizer, dispersing agent, and strengthener. It is also used as a source of bulk-fiber in cattle feed, and as an emulsifying and dispersing agent in processing certain foods for human consumption. It exists in the cell walls of higher plants. The cell wall fibers are generally made of the polysaccharide, cellulose, the most abundant polysaccharide on earth. In addition to cellulose, the secondary cell wall contains another very abundant material called lignin which is the polysaccharide that makes plants stiffer. By cooking wood chips in a solution of calcium bisulphate under heat and pressure, lignin is converted to a water soluble lignosulfonic acid (LSA) solution known as spent sulfite liquor^{31,32}. It is a low molar mass compound with an average molecular weight of approximately 5000 Daltons. Because lignins are very complex natural polymers with many random couplings, the exact chemical structure is not known, but it is considered to be that of a sulphonated polymer in which the basic unit is a propylbenzene structure similar to that of coniferyl alcohol³¹. The usefulness of commercial lignosulfonate comes from its dispersing, binding, complexing and emulsifying properties. The aromatic ring structure of lignosulfonic acid confers on plants the ability to resist attacks from microbes. LSA has been shown to have *in vitro* anti-HIV activity.

Formulations comprising the carrageenans and LSA can be prepared by adding LSA to the carrageenans, generally in an LSA-total carrageenan weight ratio of from about 20:1 to about 1:20. As in the case of compositions containing a metal salt, a solid buffer salt can be mixed with the carrageenans, usually in a weight ratio of from about 1:1 to about 10:1. The resultant mixture is then solubilized in an aqueous solution. The pH of the carrageenan-LSA formulation may then be adjusted to be from about 6.0 to about 8.0 by adding an acid such as HCl, or a base such as NaOH. LSA in aqueous solutions yields a tan to brown coloration. The intensity of which increases proportionally with the concentration used. Thus, a whitening agent such as titanium dioxide may be included in the composition. In general, the whitening agent is present in an amount of about 0.1 to about 3.0% based on total weight of the composition. The whitening agent may also contribute to the antimicrobial effect.

Without intending to be bound by any particular theory of operation, it is believed that aside whatever anti-viral activity LSA exerts on its own, LSA also functions as a dispersing agent for the carrageenans, and disentangles and elongates them, thus creating greater density of this material and greater anti-microbial potency. On the other hand, the carrageenans provide the preferred rheological properties necessary for acceptable and effective vaginal (and even rectal) administration, which cannot be achieved by LSA in and of itself because it is rather watery in nature. In some embodiments, the combination of the carrageenans and LSA acts synergistically in preventing or inhibiting sexually transmitted infections.

Compositions of the present invention may also contain a vaginally administrable drug in the aqueous formulation along with the pH controlling agent and the lambda carrageenan or the carrageenans. Preferred drugs are contraceptive agents, such as steroid hormones, disclosed in Saleh, *et al.*, U.S. Patent 5,972,372 ("Saleh"), the disclosure of which is hereby incorporated by reference. Examples of contraceptive agents useful in the present invention include progestins, ACTH, androgens, estrogens, gonadotropin, human growth hormone, menotropins, progesterone, progestins (e.g., levonorgestrel, norethindrone, 3-keto-desogestrel and gestodene), progestogen, urofollitropin, vasopressin and combinations thereof. Preferred agents include progestational compounds (e.g., norethindrone acetate and NESTORONE™ ("NES"). (i.e., 16-methylene-17.alpha.-acetoxy-19-norpregnene-3,20-dione)), and progestins (e.g., levonorgestrel (LNG)).

A preferred contraceptive agent is Nestorone 16-methylene- 17 α -acetoxy- 19-norpregn-4-ene-3, 20-dione (hereinafter "NES"), which has been identified in the literature as "ST-1435". In comparative studies using the classic bioassay of measuring progestational potency, NES was found to have progestational activity 100 times higher than that of progesterone and 10 times higher than that of levonorgestrel⁵³. Therefore, smaller amounts of NES are required to achieve ovulation inhibition. This potency combined with a lack of androgenic, estrogenic and glucocorticoid-like (hepatic glycogen deposition) activity and the lack of effects on lipid or clinical chemistry parameters, confer special advantages for the use of NES in contraceptives⁵³⁻⁵⁵. However, NES has been shown to undergo rapid metabolism and inactivation upon oral administration making it suitable for use in nursing women when given via implants or vaginal rings^{56,57}. A preferred delivery dose of NES when combined with the K/ λ carrageenan mixture in gel form is between about 75 and about 100 μ g per day, which will reach plasma levels of NES around 200 pmol/L and achieve good bleeding patterns during menus. Other preferred vaginally administrable drugs include agents for hormone replacement therapy such as estrogenic substances (e.g., ethynylestradiol) and other steroidal compounds.

Without intending to be bound by any particular theory of operation, it is believed that the carrageenans possess a dual function of imparting microbicidal properties while providing a prolonged release delivery system for a contraceptive agent or agent for hormone replacement therapy, thus enhancing the activity of the agent.

Any of the compositions described herein may further contain at least one physiologically inert ingredient, such as a physiologically acceptable preservative. Preservatives include alkyl esters of para-hydroxybenzoic acid, such as methyl paraoxybenzoate, propyl paraoxybenzoate, hydantoin derivatives, parabens, such as methyl paraben, propionate salts, triclosan tricarbonyl, tea tree oil, alcohols, farnesol, farnesol acetate, hexachlorophene and quaternary ammonium salts, such as benzalkonium chloride, zinc and aluminum salts, sodium benzoate, benzyl alcohol, benzalkonium chloride and chlorobutanol. In general, the preservative is present in an amount up to about 0.3% based on the total weight of the composition. In addition to inhibiting the growth of microorganisms that may be introduced inadvertently during manufacturing, the preservative prevents any deleterious effects that might occur to the active agents in the composition due to the presence of normal

body flora once the composition is introduced into the body. This will prolong the length of time that the active agents in the composition remain active.

In preferred embodiments, the compositions of the present invention e.g., containing the carrageenans as the sole antimicrobial agent, with or without a vaginally administrable drug, and the compositions that contain an additional antimicrobial agent such as the cationic metal salt or LSA, are administered vaginally. The present invention also includes rectal administration. The compositions may be suitably formulated e.g., into gels, creams, foams, films and suppositories, in accordance with standard techniques in the pharmaceutical industry. Gels are preferred. The formulations are preferably administered prior to sexual activity such as intercourse, usually within about one hour before such time. The application of the carrageenan-based formulation in human prevents or inhibits transmission of a sexually transmitted infection (STI), such as *Neisseria gonorrhoeae*, human papillomavirus, HSV-2 and HIV.

Yet another aspect of the present invention is directed to a method for refining a non-absorbable, carrageenan. The formulation is typically prepared by mixing a solid buffer salt and lambda carrageenan, or the carrageenan mixture, in a weight ratio of from about 1:1 to about 10:1. The mixture of solid buffer salt and carrageenan is then solubilized in water or in an aqueous solution, to make the formulation. The pH of the formulation is then adjusted to be from about 6.0 to about 8.0. This is typically achieved by the addition of an acid, such as HCl or a base, such as NaOH. In general, the viscosity of the formulation is from about 20,000 to about 100,000 CPS, preferably from about 30,000 to about 35,000 CPS. At least one physiologically acceptable preservative can be added to the formulation. Examples of such preservatives are disclosed herein. The preservative can be present in the proportions indicated in the various pharmacopoeias, and in particular in a weight ratio to the carrageenans of from about 80:1 to about 10:1, preferably from 40:1 to about 15:1.

Solid buffer salts include solid alkaline metal salts of acetic acid, citric acid and phosphoric acid, wherein the solid alkaline metal phosphate buffer includes solid mixture of tri-basic and di-basic alkali salts of phosphate, preferably in anhydrous form, wherein alkaline metal includes, but is not limited to potassium and sodium. Any physiologically acceptable buffer can be used.

Without intending to be bound by any particular theory of operation, it is believed that the carrageenans are dry powders that are extremely hygroscopic when exposed to the atmosphere. The uptake of atmospheric moisture into the dry ingredient causes clumping of the material. The problem compounded when the material is then introduced into the aqueous base solution, such that complete incorporation of the carrageenans into a homogeneous aqueous solution cannot be obtained. It is also believed that by mixing the carrageenans and at least one solid buffer salt together, the solid buffer salt absorbs the atmospheric moisture that the carrageenans would have absorbed when exposed to the atmosphere, thus preventing or substantially reducing clumping of the carrageenans. It is further believed that the process serves to increase the solubility of carrageenans in water, and achieves stabilization of the pH.

The following examples are intended to further illustrate certain embodiments of the invention and are not intended to limit the invention in any way.

Example 1. PRODUCTION OF 500 LITERS of the carrageenans

In preparing the lambda carrageenan or the carrageenan mixture, (1) the formulation ingredients should be weighed individually in a clean, dry weighing vessel; (2) the ingredient's "actual" weight, not protocol weight, should be recorded in the manufacturing production log regardless of even slight variation between the two; (3) any bulk ingredient container containing an artifact(s) or contaminate should not be used and the container should be closed, sealed, marked "CONTAMINATED" and removed from production area; (4) in process production batch should not be transferred from one vessel to another before manufacturing is completed and formulation has passed quality control testing; and (5) production vessel should remain closed during manufacturing to avoid loss of water due to evaporation, especially during any steps that require heating.

Additionally, carrageenan has proven to be stable in the solid state and the production state under a variety of adverse conditions, including freezing or autoclaving, for 24 months.

The following pertains to a procedure for that was used to make a formulation containing a carrageenan mixture of lambda (λ) and kappa-II (K-II) carrageenans (the (K-II/ λ carrageenan mixture). In the course of preparing the K-II/ λ carrageenan mixture from 100 mL laboratory size batches on to scale-up of 15 and 30 liter laboratory batches to finalizing the manufacturing procedure of 500 liter batches, it became difficult to obtain batch-to-batch

consistency of the desired formulation. The present method surprisingly overcame these difficulties and produced formulations of the K-II/ λ carrageenan mixtures having consistent batch-to-batch quality.

EQUIPMENT:

- 5 Production Vessel - IKA, EMA 9/500AIUTL, is a water jacket production vessel that allows for rapid heating and cooling of solution during production.

INGREDIENTS:

- the K-II/ λ carrageenan mixture;
- Phosphate buffer saline (PBS) [containing: NaCl - 120 mmol/L, KCl - 2.7 mmol/L,
- 10 Phosphate buffer (potassium phosphate monobasic and sodium phosphate dibasic) - 10 mmol/L - (Sigma Aldrich, Saint Louis MO);
- p-Hydroxybenzoic methyl ester (Methyl paraben) - (Nipa Laboratories, Pontypridd, UK);
- Hydrochloric Acid (HCl) - Merck, Darmstadt, Germany;
- 15 Purified water - Clean Chemical Sweden AB, Borlange, Sweden.
- Procedure

- (1). Weighed ingredients in the following quantities:

INGREDIENT	QUANTITY
Purified water (3 Parts)	484.0 kg
the K-II/ λ carrageenan mixture	15.0 kg
Phosphate buffer saline (PBS)	4.8 kg
Methyl paraben	0.5 kg
Hydrochloric acid (10%)	0.5 kg

- 20 (2). Carefully and thoroughly mixed the dry ingredients, the K/ λ carrageenan mixture and Phosphate buffer saline (PBS) together;
- (3). Inspected production vessel to ensure that mixing chamber is clean, dry and free of artifacts, and that the bottom valve is closed;
- 25 (4). Filled the production vessel with 100.0 L (Part I) of purified water and began stirring:

turbine 500 rpm and anchor 20 rpm. Water is added in 3 parts. The first part was enough to dissolve the methyl paraben. The second part aided in reducing the

temperature, sufficiently diluted the HCl so acidic hydrolysis of carrageenan did not occur while maintaining low enough solution level so when adding the carrageenan/PBS mixture, the delivery sieve could be lowered into the mixing vessel such that it did not come into contact with the base solution and was lower than the vessel access hatch so the excessive 'dusting' of the mixture was not lost. The third part completed the final concentration.

(5). Continued stirring and add 0.5 kg of methyl paraben and 0.5 kg of HCl. Closed vessel access hatch and heat water 75° to 85°C. Once this temperature was reached, we continued stirring for a minimum of 10 minutes to dissolve methyl paraben.

(6). Discontinued heating and add 250.0 kg (Part II) of purified water. Cooled solution to 25° to 30°C. The addition of the water expedited the cooling process. The solution needed to be cooled so that it was not producing steam when the next addition of ingredients was made. Besides preventing water loss when the vessel was open for the next addition, steam caused the carrageenan/PBS mixture to clump and stick to the sieve that was used in the addition;

(7). Opened access hatch and began the addition of carrageenan / PBS mixture slowly through a sieve with gentle shaking. Addition took approximately 20 minutes. Coincided the addition of the mixture with increasing the stirring speed to a maximum speed of turbin 1200 rpm and anchor 20 rpm. The viscosity of the solution increased exponentially with the addition of the carrageenans. If the stirring speed was not significant, the carrageenan formed 'hydro-sealed' clumps, which never became dissolved and incorporated into the solution, thereby rendering the batch unacceptable. ('Hydro-sealed' clumps are pockets of dry carrageenan, which are surrounded with an outside coating of semi-hydrated carrageenan, which become impenetrable to water due to carrageenan's extremely large molecular weight and flexible structure.);

(8). Closed access hatch and continued stirring at maximum speed, turbin 1200 rpm and anchor 20 rpm. Added 134.0 kg purified water (Part III) and disconnect the waterline, close valve. Heated solution to 75° to 80°C by applying 52% heat; and

(9). Checked that all the valves were closed and applied the vacuum to the vessel at 400 mbar. Stirred solution at slightly reduced speed, turbine 1100 rpm and anchor 20 rpm, under vacuum for 1.5 hr at 75° to 80°C. The constant stirring of the solution, which was necessary for even distribution and complete incorporation of ingredients, caused excessive air entrapment. The vacuum pulled this air out of the solution;

(10). Turned heating OFF, stirring OFF, and vacuum OFF. Removed Testing Sample from production vessel and tested for Control Test #1 Completed incorporation and even distribution;

Control Test #1: Complete incorporation and even distribution

Removed approximately 90 µL of the in-process mixture (used a large orifice 200 µL pipette tip to aid in removing the carrageenan solution) and mixed in 10 µL of a 0.1% methyl blue TS (1:1, isopropyl alcohol: dH₂O) in a 500 µL Eppendorf tube. The mixture in the tube should appear as an even blue color. This indicates that the K-II/λ carrageenan mixture is evenly distributed within the solution. Prepared a microscope slide with a 10 µL of this mixture; covered with a cover slip and viewed under low magnification (10X). The K-II/λ carrageenan mixture should appear as large purple strands. This indicates that the K-II/λ carrageenan mixture was completely incorporated and the solution is "PASS". If the strands are blue or large blue clumps are visible, then the K-II/λ carrageenan mixture is not completely incorporated and solution is "FAIL". Continued processing the solution under the conditions of step #9. Rechecked solution at 0.5 hour intervals until solution is "PASS".

(11). When the solution is "PASS" for Control Test #1, test for Control Test #2, pH; Control Test #2: pH

The testing sample should be cooled to 25°C ± 2 (a range of 23°C to 27°C) for testing.

The pH should be 7.0 ± 0.1 (a range of 6.9 to 7.1). This indicates that the solution's pH is uniform and the solution is "PASS". If the solution is not within the acceptable pH range (6.9 to 7.1) the solution is "FAIL". If the solution is "FAIL", the solution needs to be adjusted, as needed with either 10% HCl (to decrease the pH) or 1N NaOH (to increase the pH) in 25 mL increments until the solution is "PASS". With each incremental addition of either acid or base, thorough stirring (stirring and vacuum condition step #9, no added heat) is needed to ensure even distribution throughout batch before re-testing the pH. Recheck solution after

stirring/vacuum for 0.5 hour. Continue in this manor until solution is "PASS".

(12). When the solution is "PASS" for Control Test #2, begin cooling the mixture to 25°C

5 ± 2° (23°C to 27°C). The stirring speed, which should be OFF at this point, will need to be increased as the solution thickens upon cooling. At start, turbin OFF and anchor 20rpm, increase turbin 20 rpm / 15 mm and increase anchor 10 rpm / 30 mm, ending with turbin 1000 rpm and anchor 40 rpm. It is preferred not to increase stirring to rapidly; otherwise, air entrapment may result. If this should happen, apply the vacuum 400 mbar until solution is free of air bubbles;

10 (13). Remove Final Testing Sample from the production vessel and retest for Control Test #2 pH and for Control Test #3, Viscosity.

Control Test #3: Viscosity

The testing sample should be heated to 35°C ±2° (a range of 33°C to 37°C). To optimize performance, the viscosity should be about 30,000 to about 40,000 cP. Viscosity
15 measurements indicate that the solution's viscosity is uniform with the PC Reference sample and CCS production batches and the solution is 'PASS'. If the solution is "FAIL" obtain testing samples from the top and the bottom of production vessel and conduct Control Test #2, pH and Control Test #3, Viscosity on each sample. If the solution is still "FAIL", repeat step #9 and step #12 and retest the solution for Control Test 3#, Viscosity. If solution is
20 "FAIL" an Out of Specifications Study shall be undertaken to determine the source of out of specification production.

It was discovered that adjusting viscosity with the addition of water yields an unknown percent/concentration to the final production batch rendering the production batch unacceptable.

25 (14). When the solution is "PASS" for Control Tests #1, #2, and #3 it is an acceptable production' batch which can be processed for the final control testing. Connect the transfer tube containing a filter bag to the bottom value of the production vessel and transfer the formulation into storage containers. Retain a Test Sample for Microbiological Testing before filling applicators.

30 The final formulation prepared in the process discussed above has the following components.

Weight/Percent: 500 Liters of formulation

Component	Weight	Percent
Purified Water	484.0 kg	96.8
Methyl paraben	500 g	0.1
PBS:		
NaCl	120 mmol/L	
KCl	2.7 mmol/L	
Phosphate salts	10 mmol/L	
10% HCl	500g	0.1
the K-Π/λ carrageenan mixture	15 kg	3.0

The final formulation has a pH of about 7.0 which was adjusted by adding HCl solution and 1:1 ratio of K_3PO_4 and Na_2HPO_4 .

5 Example 2. Effect of Carrageenan on HIV Infections *in vitro*

Carrageenan has been shown to block HIV and other enveloped viruses by several laboratories including the laboratory of the PI¹⁵⁻¹⁹. Several different types of target cells and strains of HIV have been employed in these studies. Generally, 50% blocking is observed at a few micrograms/mL. This result is similar to other sulfated polysaccharides such as heparin and dextran sulfate.

10 Example 3. Intra-vaginal viral infection studies - HSV-2/Mouse

Because HIV does not infect laboratory animals and the need of employing an *in vivo* system that more closely mimicked the physiological events of sexual transmission of pathogens in humans, it was necessary to establish system that used a human virus that was similar to HIV and infectious to mice. Besides being the first and the principal *in vivo* system to evaluate the potential of candidate microbicides in blocking viral infection, the HSV-2/mouse (Balb/C) system is widely utilized by most investigatory groups engaged in the development of a microbicide. An important difference between the system established by Phillips²⁰⁻²² and other systems is the utilization of viral dose range comparison. The standard viral challenge dose, 100% infection dose or 10^4 pfu, used by others for evaluation of a microbicide is rate limiting. The large majority of the microbicides under development, as well as many of the OTC spermicides will show a significant rate of protection against HSV-2 infection at this viral challenge doses. However, Phillips has utilized a virus concentration

method that will enable evaluation at viral challenge doses of 10^5 , 10^6 , and $1,000 \times 100\%$ infection dose.

Using this viral challenge dose system, a comparison study was conducted to evaluate the comparison protection rates of a number of microbicides under development, OTC spermicides and lubricants, and possible formulations for use as a placebo in the clinical trials to evaluate efficacy of a microbicide. In addition to a composition of the present invention containing the K-II/ λ carrageenan mixture (also referred to herein as the "K/ λ carrageenan composition"), comparative test formulations were: microbicides under development such as BufferGel™ and No Fertil, OTC spermicides: K-Y Plus® Gynol II®, and Advantage S™; OTC vaginal lubricants: Replens® and K-Y Jelly®; and possible placebo formulations: 2.5% Carbopol® and 2.5% methyl cellulose.

Test formulations fell into three categories with respect to efficacy in protecting mice from vaginal HSV-2 infection. At the viral challenge dose of 10^4 pfu, with the exception of K-Y Jelly, Carbopol and methyl cellulose, all formulations provided a significant level of protection against infection from HSV-2. However, at the viral challenge dose of 10^5 , with the exception of the K-II/ λ carrageenan composition, all formulations only provided a minimum level of protection. The K-II/ λ carrageenan composition was the only formulation still affording a level of protection against viral infection at the viral challenge dose of 10^6 pfu.
By evaluating various formulations in the viral dose range comparison system the resulting data was the first demonstration of the unexpected high level of protection against viral infection that the K-II/ λ composition provides.

Therefore, it can be concluded that the HSV-2/mouse system can be employed as a means by which candidate microbicides can be evaluated and compared under the same testing conditions to identify potential effective microbicides.

Example 4. Duration of activity - HSV-2/Mouse

One of the criteria set forth by UNAIDS (World Health Organization, AIDS branch) for an ideal microbicide states 'it should be active upon insertion and for a long period of time,' giving a woman more flexibility in product use. Additionally, the time course for infection by cell-free or cell-associated HIV to occur may not be immediate. The HSV-2/mouse system can be employed to evaluate the duration of time that a microbicide would retain activity. This is done by intra-vaginal application of a test formulation, waiting a set

period of time, and then challenging mice with a known dose of virus. "Duration of activity" testing was conducted using Gynol II® (a 2% N-9 containing OTC spermicide), BufferGel® (a low pH microbicide under development) and the K-II/λ carrageenan composition, at five minutes and 1.5, 3, 6 and 18 hours following formulation application. By the 1½-hour time point, Gynol II® no longer afforded any protection against infection and BufferGel® had dropped to being only 30% effective. BufferGel's efficacy continued to drop over time and no longer afforded any protection by 6 hours. In marked contrast, the K-II/λ carrageenan composition remained 85-100% effective in protecting against HSV-2 infection up to 6 hrs and remained 72% effective at 18 hrs. The K-II/λ carrageenan composition continued to retain some level of activity for up to 24 hours. See fig. 1. The extended duration of protection from viral infection is unique to carrageenan, in particular K-II/λ carrageenan composition.

Example 5. Intra-rectal viral infection studies - HSV-2/Mouse

Ideally, a microbicide that was effective in protecting against infection by HIV could be used rectally as well as vaginally. Using an intra- rectal viral challenge modification of the HSV-2-/mouse system an evaluation of the efficacy and safety of a microbicide was explored.

Pre-treatment of the rectum with the K-II/λ carrageenan composition significantly reduced the number of animals that became infected following rectal challenge with HSV-2, compared to pretreatment with PBS or methylcellulose (an inert placebo)²³

Example 6. Effect of K-II/λ carrageenan composition on vaginal flora

It is important that the use of a microbicide does not disrupt the balance of the natural vaginal flora. *In vitro* studies indicated that carrageenan did not enhance or inhibit the growth rate of *Lactobacillus acidophilus*, the most common bacterium present in the vaginal flora. A study conducted in 35 women participating in a Phase I clinical trial for the vaginal safety of the K-II/λ carrageenan composition showed no significant change in vaginal flora, as measured by the presence or absence of bacterial vaginosis¹³.

Example 7. HIV/Mouse viral transport system

Although mice can not be infected with HIV, it has been shown that when active or inactivated virus is instilled into the vagina of mice, virus can be subsequently detected in the lymph nodes by the use of reverse transcriptase polymerase chain reaction (RT-PCR)²⁴

Evidence has been presented that dendritic cells played a role in the uptake of virus and subsequent transport to the lymph nodes. This conclusion is in agreement with studies implicating dendritic cells in the initial stage of sexual transmission of HIV²⁵.

Results indicate that the K-II/ λ carrageenan composition is efficacious in preventing HIV from reaching the lymph node, presumably by blocking HIV transport from the vagina via dendritic cells.

HIV transport using a mouse system and AldritholTM-2 inactivated virus were used. This is a standard method for inactivating HIV that does not alter the viral envelope. The spleen and the lymph nodes were assayed for the detection of HIV in order to establish the spleen as an alternate repository site for HIV. The spleen (as opposed to the lymph nodes) allows for obtaining relatively larger amounts of RNA for performing RT-PCR for the detection of HIV. In addition, extraction of spleens is less time consuming than removal of the lymph nodes thereby lessening the probability of RNA degradation.

To determine the efficacy of the K-II/ λ carrageenan composition in preventing HIV from crossing the cervical/vaginal barrier, mice were randomized into three groups: 1) non-treated PBS control mice; 2) mice pre-treated with methyl cellulose (inert placebo); and 3) mice pretreated with the K-II/ λ carrageenan composition. Results are shown on the Southern Blot in Fig. 2 and the table below.

Treatment	PT-PCR +/-total	Percentage Positive (Infected)
PBS	16/22	72%
Methyl Cellulose	7/10	70%
K-II/ λ carrageenan composition	2/22	9%

Data from PBS (control) and methyl cellulose treated and mice treated with the K-II/ λ carrageenan composition show that the K-II/ λ carrageenan composition significantly reduced the number of positive (i.e., infected) animals, and that methyl cellulose had no effect as compared to PBS (control). The data also indicate that the K-II/ λ carrageenan composition was effective in preventing HIV from leaving the vaginal vault.

Example 8. Cell Trafficking/Mouse System

It has previously been suggested that sexual transmission of HIV could be mediated by HIV-infected lymphocytes or macrophages in semen that cross the genital tract epithelium^{26,27}. In order to test the hypothesis that mononuclear blood cells traffic from the vaginal vault through intact epithelia, double-vitally-stained activated mononuclear blood cells (mouse) were placed in the vagina of mice. Four hours later, animals were sacrificed and iliac and inguinal lymph nodes and the spleen were removed and cells were dissociated and count by fluorescence microscopy. Numerous double-stained cells were observed in the iliac and inguinal lymph nodes and the spleen^{28, 29}. To evaluate the effect that the K-II/λ carrageenan composition may have on blocking this process, animals were pre-treated with the test formulation prior to instillation of labeled cells.

Mouse	Inoculation	Inguinal & Iliac Lymph nodes	Spleen
1	Macrophages	36	555
2	Macrophages	52	366
3	Macrophages	59	672
4	Macrophages	87	786
5	Macrophages	61	357
6	Macrophages	40	859
7	Macrophages	54	312
8	K-II/λ carrageenan + Macrophages	4	30
9	K-II/λ carrageenan + Macrophages	4	6
10	K-II/λ carrageenan + Macrophages	6	48
11	K-II/λ carrageenan + Macrophages	3	53
12	K-II/λ carrageenan + Macrophages	3	3
13	Methyl cellulose + Macrophages	14	120
14	Methyl cellulose + Macrophages	27	245
15	Methyl cellulose + Macrophages	38	96

Donor's cells were present both in the iliac and inguinal lymph nodes and in the spleen. When mice received only a vaginal inoculation of macrophages, the recipient animals had an average of 55 labeled donor's cells in the draining lymph nodes and of 558 cells in the spleen, respectively. In mice that received a vaginal pre-inoculation of K-II/λ carrageenan

composition (indicated in table above as "K-II/ λ carrageenan") an average of only 4 cells were counted in the draining lymph nodes, and an average of only 28 were observed in the spleen. The difference between untreated and K-II/ λ carrageenan composition-treated animals was significant. When the recipients were pre-inoculated with methyl cellulose, the number of donor's cells that reached lymph nodes and spleen averaged 26 in the lymph nodes and 153 in the spleen. The difference between K-II/ λ carrageenan composition-treated mice and methyl cellulose-treated mice was significant, whereas the difference between untreated mice and methyl cellulose pre-inoculated mice was not significant. No fluorescent cells were observed in control mice that had been inoculated with frozen-thawed CMTMR stained macrophages.

Example 9 Microbicide effect on papillomavirus

The K-II/ λ carrageenan composition has also been proven effective on blocking bovine papillomavirus (BPV) foci formation *in vitro* (data not shown). The K-II/ λ carrageenan composition is efficacious in preventing human papillomavirus (HPV) from transforming human vaginal explants in a xenograft system. The SKID mouse xenograph system employs explants of human vaginal tissue rolled into cylindrical tubes that are grafted subcutaneously on NOD/SKID (immunodeficient) mice²⁹. The grafts are allowed to heal for two weeks, at which time one end of the tube is opened and a test compound is instilled followed by HPV challenge. In experiments evaluating the K-II/ λ carrageenan composition, in 14 out of 14 saline treated control explants were transformed. In contrast, only 1 out of 17 explants treated with the K-II/ λ carrageenan composition was transformed (data not shown).

Example 10. Effects of the K/ λ carrageenan mixture in dilution assay

The K/ λ carrageenan mixture is also effective at high dilutions as demonstrated in the HSV-2 mouse system. A 3% K-II/ λ carrageenan composition was diluted in PBS to make 1:1, 1:5, 1:25, 1:50, 1:100, and 1:200 dilutions. Dilute solutions were vaginal administered to mice followed by 10^4 (100% infection dose) of HSV-2. The results from these experiments are unexpected. Instead of observing a dose dependent decrease in the anti-viral protection rate the K-II/ λ carrageenan composition dilution of 1:50 retained most of the anti-viral protection rate as less dilute solutions. Furthermore, significant activity was retained even with the 1:200 solution. See Fig. 11.

Example 11. Effects of the K-II/ λ carrageenan composition-based formulations against HIV

Compounds have been identified which when added to, or bound to the carrageenans of the present invention, significantly increase efficacy in blocking HIV infection of PBMCs *in vitro*. Studies on the effectiveness of Zn-carrageenan and LSA-carrageenan on blocking HIV infection of PBMCs have shown that both formulations are more effective than a compositions containing the carrageenans alone at lower concentrations. The testing results are shown in Fig. 3.

Example 12. Effects of LSA-carrageenan against HSV-2

Results indicate that LSA-carrageenan is more efficacious in blocking HIV infection than the carrageenans. (See Fig. 4.) Originally LSA did not seem to be an ideal candidate compound for a microbicide due to the fact of its brown coloration. However, it was found that a concentration of 0.25%, LSA is highly effective and imparts negligible coloration when formulated. In order to ensure that LSA would not impart discoloration, white cotton fabric was soaked overnight in 3% LSA and then rinsed with tap water; the results revealed no change in the color of the fabric. LSA-carrageenan was compared to carrageenan in the HSV-2/mouse system in order to determine efficacy in blocking viral infection *in vivo*. Preliminary results showed that LSA-carrageenan was more efficacious than carrageenan in blocking viral infection.

In addition to the results presented above, LSA-carrageenan was compared to the K-II/ λ carrageenan composition alone at a viral challenge dose of 10^6 pfu, in three separate experiments. LSA-carrageenan was significantly more effective than the K-II/ λ carrageenan composition alone in all experiments. The addition of other sulfated polymers to K-II/ λ carrageenan composition did not increase the effectiveness of the formulation. For example, the addition of 5% dextran sulfate or 5% heparin to K-II/ λ carrageenan composition had no effect on efficacy against HSV-2 infection in mice.

Evaluation of K-II/ λ carrageenan composition (referred to in the three tables below as "Carrageenan") Formulations with and without LSA

HSV-2 10^6 pfu viral dose is equivalent to 100 times the viral dose that would infect all unprotected mice. It is necessary to use such high doses of virus because carrageenan is extremely effective at inhibiting viral infection.

Each formulation is initially tested in a total of 20 mice. Compounds or formulations that show a blocking effect are assayed again in another 20 mice. The number of mice infected is an average.

5	FORMULATION	# MICE INFECTED	% INFECTED
	TOTAL # MICE		
	3% Carrageenan	14/20	70
	1% Carrageenan	20/20	100
10	0.5% Carrageenan	20/20	100
	3% Carrageenan + 3% LSA	4/20	20
	3% Carrageenan + 1% LSA	2/20	10
	3% Carrageenan + 0.5% LSA	4/20	20
	3% Carrageenan + 0.25% LSA	5/20	25
15	3% Carrageenan + 0.1% LSA	7/20	35

The viral dose is 100 times the 100% infection rate and no compound other than the minimal effect of 3% carrageenan has had any effect at such a high virus dose.

Subsequently, LSA was assayed without Carrageenan to better evaluate its inhibitory properties. LSA was added to the inert thickener, methylcellulose, to maintain the same viscosity that vaginal products (lubricants, spermicides, and microbicides) generally have. (Data shown below.)

Evaluation of LSA without carrageenan

25	FORMULATION	# MICE INFECTED	% INFECTED
	TOTAL # MICE		
	3% Carrageenan	14/20	70
	3% LSA - methylcellulose	8/20	40
	1% LSA - methylcellulose	8/20	40

LSA proved to be more effective than carrageenan, showing better blocking of HSV-2 infection than carrageenan. However, the combination of the two ingredients out-performed either one alone.

Example 13. Use of LSA in Microbicides

LSA is effective as a microbicide against HSV-2 infection, HIV, and other STI's, with or without carrageenan. The sulfated polymer LSA is effective in protecting epithelial cells

in vitro against HIV infection and mice from HSV-2 infection. The inhibitory effect may be observed with other enveloped viruses such as the human pathogen, human T cell leukemia virus. In addition, epithelial cells are protected against the human papillomavirus, which is not an enveloped virus. The inhibitory efficaciousness of LSA may thus extend to a broader range of STI's. The testing results are shown in Fig. 5.

Example 14. Effects of Zn-Carrageenan against HSV-2

Studies on the effectiveness of Zn-carrageenan against HSV-2 infection have been conducted *in vitro* and *in vivo*. *In vitro* studies assayed the effect of Zn salts alone in preventing plaque formation in the HSV-2 plaque assay⁴¹. Zn salts were found to have an IC₅₀ at a 50 mM concentration in reducing plaque formation. It was observed that Zn-carrageenan is significantly more effective than carrageenan or Zn salts alone in preventing plaque formation IC₅₀ < 10 µg/mL, or < 25 mM. The testing results are shown in Fig. 6.

Zn-carrageenan has also been evaluated in the HSV-2/mouse system (see Fig. 7). In order to compare Zn-carrageenan with the OTC spermicide K-Y Plus and the K-II/λ carrageenan composition, HSV-2 viral challenge doses ranging from 10³ pfu or 50% infection dose, to 10⁷ pfu or 1,000 x 100% infection dose was also used. Applicants had determined that K-II/λ carrageenan composition could protect some animals at a viral challenge dose of 10⁶ pfu or 100 x 100% infection dose. No other candidate microbicide tested was able to afford protection at this viral dose. In preliminary studies it has been observed that Zn-carrageenan significantly protect mice against HSV-2 infection at this dose as well as at a viral challenge dose of 10⁷ or 1,000 x 100% infection dose. The fact that the addition of Zn to the K-II/λ carrageenan composition (to form a complex) increased the level of anti-viral protection was most unexpected.

Example 15. Zn-carrageenan duration of activity

The K-II/λ carrageenan composition remains active in the mouse vagina for an extended period of time. Similar experiments were carried out to compare Zn-carrageenan to two OTC spermicides, Advantage S and Conceptrol, for duration of activity. It was observed that Zn-carrageenan did not lose any level of activity in 6 hours, where Advantage S and Conceptrol showed a 50% reduction in activity at 1.5 hours and by 3 hours were no longer able to afford protection (see Fig. 8).

Example 16. Zn-carrageenan efficacy post-viral challenge

A microbicide that was able to be effective even if administered following exposure to a virus would extend product use to include women who were not able to use the product until after intercourse had already occurred e.g., women who fell victim to rape. Previously, researchers have been unable to identify a microbicide that might afford such protection. Zn-carrageenan is able to afford protection against HSV-2 infection in mice post-viral challenge. As the data below demonstrate, Zn-carrageenan is exceptional in that it demonstrated activity for up to 4 hours post-viral exposure (see Fig. 9). This finding is remarkable in light of Applicants' observations that K-II/ λ carrageenan composition did not prevent infection post viral challenge unless administered immediately following HSV-2 challenge.

10 Example 17. Contraceptive Microbicide for Dual Protection

The K-II/ λ carrageenan composition remains in the vagina for up to 24 hours, enabling a once-daily application for protection against HIV and its use as a vaginal delivery system for a contraceptive hormone. The feasibility of delivering various steroids vaginally has been thoroughly investigated with the recent development of contraceptive vaginal rings⁴³. It has been shown that steroids applied directly to the vaginal mucosa are quickly absorbed, and only very small doses are needed to achieve the desired contraceptive effect ⁴⁸⁻⁵². In addition, vaginal delivery is usually accompanied by diminished undesirable side effects that are often associated with oral contraceptives.

The vaginal formulations of the present invention provide dual protection as a combination microbicide/contraceptive that have a further advantage of enhancing user motivation for compliance. The contraceptive hormone NES is a preferred contraceptive agent. This synthetic progestin has been shown to be an exceptionally potent molecule. Using classic bioassays of measuring the progestational potency, NES has proven to be 100 times more active than progesterone and only very small quantities of NES are required to suppress luteal activity. Additionally, extensive toxicology studies of NES have been conducted.

25 Example 18. Diffusion of NES from the K/ λ carrageenan mixture

In order for the formulation containing the K-II/ λ carrageenan composition and NES (hereinafter "CARRA /NES") to be an effective contraceptive, it is essential that NES be released from the carrageenan and absorbed through the vagina. We have carried out *in vitro* assays to determine if NES is released from CARRA/NES.

We examined diffusion of NES through a dialysis membrane with a molecular weight cutoff of 1000. The molecular weight of NES is 370. NES diffused from the dialysis bag at a constant rate, as measured by HPLC. Results are illustrated in Fig. 10. These results demonstrate that NES is not bound to carrageenan. However, the rate of diffusion observed through the dialysis membrane cannot be related to the rate of diffusion that would be observed in the human vagina as the rate of diffusion was dependant on the surface area of the dialysis bag. Conditions in the vagina would be different.

We also conducted an experiment that involved centrifuging CARRA/NES through an Ultrafree-15 centrifugal filter and tube assembly at 2000 g for 99 minutes, to calculate percentage of NES released. The centrifuge filter is a device that fits into a centrifuge tube. The device has a flouted filter in the bottom that allows molecules with MW under 500 to pass through. Using this device, over 98% of the added NES was recovered in filtrate. This experiment confirms that NES is not bound to carrageenan.

Example 19. CARRA/NES (release rates)

CARRA/NES

Solutions of increasing concentrations of NES were formulated into the K-II/ λ carrageenan composition to establish compatibility of the two compounds. A concentration of 500 $\mu\text{g/mL}$ of NES in the K-II/ λ carrageenan composition retained the rheological properties, as measured by pH, viscosity, homogeneity and ocular appearance, and exhibited retention of strength, as measured by the HSV-2/mouse assay. This concentration of NES is 40 times higher than the predicted concentration needed for a high-dose formulation of 100 pg/mL .

Diffusion of NES from CARRA/NES was investigated by two different methods, membrane dialysis and Ultrafree-15 centrifugation. In the membrane dialysis experiments, the membrane cutoff is 1,000, and diffusion of NES was measured by HPLC. Results indicate that NES is not bound to the negatively charged carrageenan and, although the rate of diffusion through a dialysis membrane is different than in vivo systemic absorption, diffusion occurs in a time dependent manner. In the Ultrafree-15 centrifugation experiments, a Millipore, Ultrafree-15 centrifugal filter and tube assembly was employed, which allows the passage of molecules of a MW < 500 pass through; NES MW is 370. The use of this technique demonstrated that 98.6% of NES was recovered.

INDUSTRIAL APPLICABILITY

The present invention is useful in prevention and inhibition of transmission of sexually transmitted infections.

- 5 All patent and non-patent publications cited in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All these publications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated as being incorporated herein by reference.
- 10 Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of this invention.

REFERENCES

1. Butini, L. *et al.* Intercellular adhesion molecules (ICAM)-1, ICAM-2 and ICAM-3 function as counter receptors for lymphocyte function-associated molecule 1 in human immunodeficiency virus-mediated syncytia formation. *Eur J Immunol* 24, 2191-2195 (1994).
2. Food and Drug Administration. GRAS (Generally recognized as safe) food ingredients: Carrageenan. FDA Publications PB-221 206, (1972).
3. Benitz, K.F., Abraham, R., Golberg, L. & Coulston, F. Carrageenan: an ulcerogenic agent. *Toxicol. Appl. Pharmacol.* 22, 282 (1972).
4. Fox, M.R.S. & Jacobs, R.M. Metal Ions in Biological Systems., pp. 214-248 (Marcel Decker, Inc., 1986).
5. Luscombe, D.K. & Nicholls, P.J. Acute and subacute oral toxicity of AHR-2438B, a purified sodium lignosulphonate in rats. *Fd. Cosmet. Toxicol.* 11, 229-237 (1973).
6. Naess, B. The effect of microbial and animal proteinases on peptide- and protein lignosulphonic acid complexes in agar gel. *Acta Vet. Scand.* 12, 592-600. 1971. Ref Type: Abstract
7. Samman, S. & Roberts, D.C.K. The effect of zinc supplements on plasma zinc and copper levels and the reported symptoms in healthy volunteers. *Med. J. Australia* 146, 246-249 (1987).
8. U.S.EPA. Health Effects Assessment of for Zinc (and Compounds). EPA/540-1-96-048. 1984. Washington, D.C., US Environmental Protection Agency, Office of Research and Development. Ref Type: Data File
9. Walden, J.T. & Derreth, D. FDA New Release 72/55. *FDA Publications* 72/55, (1972).
10. Walker, A.P. *et al.* Test guidelines for the assessment of skin tolerance of potentially irritant cosmetic ingredients in man. *Fd. Chem. Toxic.* 35, 1099-1106 (1997).
11. Weiner, M.L. Intestinal transport of some macromolecules in food. *Fd. Chem. Toxic.* 26, 10, 867-880 (1988).
12. Food and Drug Administration. Study of mutagenic effects of calcium carrageenan (FDA No. 71-5). FDA Publications PB-221 820, (1972).
13. Elias, C.J. *et al.* Colposcopic Evaluation of a Vaginal Gel Formulation of iota-Carrageenan. *Contraception* 56, 387-389 (1997).

14. Lines, A.D. Value of the K+ Salt of Carrageenan as an Agar Substitute in Routine Bacteriological Media. *Applied and Environmental Microbiology* 34, 637-639 (1977).
15. Phillips, D.M. & Tan, X. Mechanism of trophoblast infection by HIV. *AIDS Res Hum Retroviruses* 9, 1697-1705 (1992).
- 5 16. Baba, M. *et al.* Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. *Antiviral Res* 9, 335-343 (1988).
17. Baba, M. *et al.* Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. *Proc Natl Acad Sci* 85, 6132-6126 (1988).
- 10 18. Pearce-Pratt, R. & Phillips, D.M. Studies of adhesion of lymphocytic cells: Implications for sexual transmission of human immunodeficiency virus. *Biol Reprod* 48, 431-445 (1993).
19. Pearce-Pratt, R. & Phillips, D.M. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of HIV-1. *Biol Reprod* 54, 173-182 (1996).
- 15 20. Maguire, R.A., Zacharopoulos, V.R. & Phillips, D.M. Carrageenan-N9 Spermicides for Preventing Pregnancy and Sexually Transmitted Infections. *Sex Transm Dis* 25, 494-500 (1998).
21. Phillips, D.M. Perspectives in Drug Discovery and Design. Fantini, J. & Sabatier, J.M. (eds.), pp. 213-223 (1996).
- 20 22. Zacharopoulos, V.R. & Phillips, D.M. Vaginal formulations of carrageenan protect mice from herpes simplex virus infection. *Clin. Diag. Lab. Immunol.* 4, 465-468 (1997).
23. Phillips, D.M. & Zacharopoulos, V.R. Nonoxynol-9 Enhances Rectal Infection by Herpes Simplex Virus in Mice. *Contraception* 57, 341-348 (1998).
24. Masuner, C. *et al.* Dendritic cells route Human Immunodeficiency Virus to lymph nodes after vaginal or intravenous administration to mice. *J Virol* 72, 7822-7829
25 (1998).
25. Masuner, C. *et al.* Dendritic Cells in Fundamental and Clinical Immunology. Ricciardi-Castagnoli (ed.), pp. 411-414 (Plenum Press, New York, 1997).
26. Anderson, D.J. Mechanisms of HIV-1 transmission via semen. *J. NIH Res.* 4, 104-111
30 (1992).
27. Levy, J.A. The transmission of AIDS: the case of the infected cell. *JAMA* 259, 3037-

3038 (1988).

28. Zacharopoulos, V.R., Perotti, M.E. & Phillips, D.M. A role for cell migration in the sexual transmission of HIV? *Current Biol.* 7, 534-537 (1997).
29. Howett M.K., K.J.W.C.K.D. Human xenografts. A model system for human
5 papillomavirus infection. *Intervir.* 31, 109-115 (1990).
30. Jerse, A.E. Experimental gonococcal genital tract infection and opacity protein expression in estradio-treat mice. *Infect Immun* 67, 5699-5708 (1999).
31. Kolopp, M. *et al.* Predictive value of an in vitro model for skin irritation (SkinEthic) applied to the testing of topical vehicles for SDZ ASM 981. *Proc.Clin.Dermatol.* 2000
10 Singapore 141. 1998. Ref Type: Abstract
32. Mitsuya, H. *et al.* Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. *Science* 240, 646-649 (1988).
33. Suzuki H, T.T.I.K.Y.S.Y.N.T.S. Lignosulfonate, a water-solubilized lignin from the waste liquor of the pulping process, inhibits the infectivity and cytopathic effects of
15 Human Immunodeficiency Virus *in Vitro*. *Agric Bid Chem* 53, 3369-3372 (1989).
34. Baba, M., Schols, D., Pauwels, R., Nakashima, H. & De Clercq, E. Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: a new strategy towards ADS chemotherapy. *JAIDS* 3, 493-499 (1990).
35. NRC (National Research Council). Recommended Dietary Allowances. (National
20 Academy Press, Washington D.C., 1989).
36. Nicklin, S. & Miller, K. Effect of orally administered food-grade carrageenans on antibody-mediated and cell-mediated immunity in the inbred rat. *Fd. Chem. Toxic.* 22, 8, 615-621 (1984).
37. CEAMSA (Compania Espanola de Algas Marmnas, S.A. Technical Information 1999-
25 2000. 1999. South America. Ref Type: Data File
38. ATSDR (Agency for Toxic Substances and Disease Registry). Toxicological Profile for Zinc. *Agency for Toxic Substances and Disease Registry, U. S. Public Health Service, Atlanta, GA.* 121 pp (2001).
39. Haraguchi, Y., Sakurai, H., Hussain, S., Anner, B. & Hoshino, H. Inhibition of HIV-1
30 Infection by Zinc Group Metal Compounds. *Antiviral Res* 43, 123-133 (1999).
40. Sergio, W. Zinc Salts that may be Effective Against the ADS Virus HIV. *Medical*

Hypotheses 26, 253 (1988).

41. Arens, M. & Travis, S. Zinc Salts Inactivate Clinical Isolates of Herpes Simplex Virus In Vitro. *J Clin Microbiol* 38, 1758-1762 (2000).
42. Tennican, P., Carl, G., Frey, J., Thies, C. & Chvapil, M. Topical Zinc in the Treatment
5 of Mice Infected Intravaginally with Herpes Genitalis Virus. *Proceedings of the Society for Experimental Biology and Medicine* 164, 593-597 (1980).
43. Alvarez-Sanchez, F., Brache, V., Jackanicz, T. & Faundes, A. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles. *Contraception* 46, 387-397 (1992).
- 10 44. Mishell, D.J., Lumkin, M. & Jackanicz, T. Initial clinical studies of intravaginal rings containing norethindrone and norgestrel. *Contraception* 12, 253 (1975).
45. Ballagh, S., Mishell, D., Jackanicz, T., Lacarra, M. & Eggena, P. Dose-finding study of a contraceptive ring releasing norethindrone acetate/ethinyl--estradiol. *Contraception* 50, 535-549 (1994).
- 15 46. Sivin, I., Mishell, D.J., Victor, A. & et al. A multicenter study of levonorgestrelestradiol contraceptive vaginal rings I - use of effectiveness. *Contraception* 24, 341-358 (1981).
47. Sivin, I., Mishell, D.J., Victor, A. & et al. A multicenter study of levonorgestrelestradiol contraceptive vaginal rings II - subjective and objective measures of effects. An international comparative trial. *Contraception* 24, 359-376 (2001).
- 20 48. Fanchin R *et al.* Transvaginal administration of progesterone: dose-response data support a first uterine pass effect. *Obstet Gynecol* 90, 396-401 (1997).
49. Cicinelli, E., Cignarelli, M., Sabatelli, S. & et al. Plasma concentrations of progesterone are higher in the uterine artery than in the radial artery after vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. *Fertil Steril*
25 69,471-473 (1998).
50. Rigg, L., Milanes, B., Villanueva & Yen, S. Efficacy of intravaginal and intranasal administration of micronized estradiol-17B. *JCE&M* 45, 1261-1264 (1977).
51. Martin, P. *et al.* Estradiol, estrone, and gonadotropin levels after use of vaginal estradiol. *Obstet & Gyn* 63,441-444 (1984).
- 30 52. Schiff, I., Tulchinsky, D. & Yan, K. Vaginal absorption of esterone and 17B-estradiol. *Fertil Steril* 28, 1063-1066 (1977).

53. Kumar, N., Koide, S., Tsong Y & Sundaram, K. Nestorone: a progestin with a unique pharmacologic profile. *Steroid* 65, 629-636 (2000).
54. Odell, V., Lithell, H., Selinus, I. & Vessby, B. Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing 5T1435. *Contraception* 31, 130 (1985).
55. Robins, A. & Bardin, C. Nestorone Progestin - the ideal progestin for use in controlled release delivery systems. *Ann N Y Acad Sci* 828, 38-46 (1997).
56. Massai, R., Diaz 5, Jackanicz, T. & Croxatto RB. Vaginal rings for contraception in lactating women. *Steroid* 65, 703-707 (2000).
- 10 57. Lahteenmaki PLA, Daz 5, Miranda P & Croxatto KB. Milk and plasma concentrations of the progestin ST 1435 in women treated parenterally with ST 1435. *Contraception* 42, 555-562 (1990).
58. World Health Organization. Microdose intravaginal levonorgestrel contraception: a multicentered clinical trial I. *Contraception* 41, 105-124 (1990).
- 15 59. Yen, S. Reproductive Endocrinology. Yen SSC and Jaffe RB (ed.), pp. 200-236 (W.B. Saunders Co, Philadelphia, 1986).
60. Henzl, M. Reproductive Endocrinology. Yen SSC and Jaffe RB (ed.), pp. 243-682 (W.B. Saunders Co., Philadelphia, 1986).
61. Brache V. *et al.* Ovarian function during use of vaginal rings delivering three different doses of Nestorone. *Contraception* . 2001. Ref Type: In Press
- 20 62. Fraser I *et al.* Vaginal epithelial surface appearances in women using vaginal rings for contraception. *Contraception* 61, 13 1-138 (2000).
63. Couch, R.C. A 12-month systemic toxicity study of subdermal implant for 5T1435 in female cynomolous monkeys. New Mexico Regional Primate Research Laboratory, Mew Mexico State University Holloman AFB New Mexico. Population Council Files. 1992. Ref Type: Unpublished Work
- 25 64. Lahteenmaki, P., Weiner, E., Johansson, E. & Luukkainen, T. Contraception with subcutaneous capsules containing 5T1435. Pituitary and ovarian function and plasma levels of 5t1435. *Contraception* 23, 63-75 (1981).
- 30 65. Lahteenmaki P, Weiner E, Johansson E & Luukkainen T. Pituitary and ovarian function during contraception with one subcutaneous implant releasing a progestin, 5T1435.

- Contraception* 25, 299-306 (1982).
66. Haukkamaa, M., Laurikka-Routti, M. & Heikinheimo, O. Transdermal absorption of the progestin 5T1435: Therapeutic serum steroid concentrations and high excretion of the steroid in saliva. *Contraception* 44, 269-276 (1991).
- 5 67. Laurikka-Routti, M., Haukkamaa, M. & Lahteenmaki, P. Suppression of ovarian function with the transdermally given synthetic progestin 5T1435. *Fertil Steril* 58, 680-684 (1992).

CLAIMS

1. An aqueous antimicrobial composition, comprising an effective amount of an antimicrobial agent comprising carrageenans which are lambda carrageenan in an amount of at least about 50% by dry weight of said carrageenans, remainder of said carrageenans being at least one non-lambda carrageenan, and a physiologically acceptable pH controlling agent.
2. The antimicrobial composition of claim 1, said amount of lambda carrageenan is at least about 75% by dry weight of said carrageenans.
3. The antimicrobial composition of claim 1, said amount of lambda carrageenan is at least about 85% by dry weight of said carrageenans.
4. The antimicrobial composition of claim 1, said amount of lambda carrageenan is at least about 95% by dry weight of said carrageenans.
5. The antimicrobial composition of claim 1, wherein said at least one non-lambda carrageenan comprises iota carrageenan.
6. The antimicrobial composition of claim 1, wherein said at least one non-lambda carrageenan comprises kappa carrageenan.
7. The antimicrobial composition of claim 1, wherein said at least one non-lambda carrageenan comprises kappa and iota carrageenan.
8. The antimicrobial composition of claim 1, wherein said at least one non-lambda carrageenan is kappa-II carrageenan.
9. The antimicrobial composition of claim 8, wherein said kappa-II carrageenan is present in said composition in an amount of about 1 to about 15% based on dry weight of said carrageenans.
10. The antimicrobial composition of claim 9, wherein said kappa-II carrageenan is present in said composition in an amount of about 3 to about 6% based on dry weight of said carrageenans.
11. The antimicrobial composition of claim 1, wherein said physiologically acceptable pH controlling agent comprises phosphate buffered saline (PBS).
12. The antimicrobial composition of claim 1, further comprising a physiologically acceptable preservative.

13. The antimicrobial composition of claim 1, wherein said effective amount of said antimicrobial agent is about 1 to about 5% by total weight of said composition.
14. The antimicrobial composition of claim 1, wherein said effective amount of said antimicrobial agent is about 3% by total weight of said composition.
- 5 15. The antimicrobial composition of claim 1, wherein said antimicrobial agent comprises about 85% lambda carrageenan and about 15% kappa-II carrageenan, each based on dry weight of said carrageenans, and wherein said antimicrobial agent is present in an amount of about 3 % of said composition.
16. The antimicrobial composition of claim 1, having a pH of about 3.5. to about 8.5.
- 10 17. The antimicrobial composition of claim 16, wherein the pH is about 6.8 to about 7.2.
18. A sexually transmitted infection (STI) inhibiting composition, comprising an effective amount of an antimicrobial agent comprising carrageenans which are lambda carrageenan in an amount of at least about 50% by dry weight of said carrageenans, remainder of said carrageenans being at least one non-lambda carrageenan, and a
- 15 physiologically acceptable pH controlling agent.
19. An aqueous antimicrobial composition, comprising: (a) a physiologically acceptable pH controlling agent; and (b) an effective amount of an antimicrobial agent comprising a complex of carrageenans which are lambda carrageenan in an amount of at least about 50% by dry weight of said carrageenans, remainder of said carrageenans
- 20 being at least one non-lambda carrageenan, and an antimicrobial, physiologically acceptable water-soluble cationic metal salt.
20. The composition of claim 19, wherein said metal is zinc, copper, or silver.
21. The composition of claim 19, wherein said metal salt is zinc acetate.
22. The composition of claim 19, wherein said metal salt is zinc lactate.
- 25 23. The composition of claim 19, wherein said metal salt is present in an amount of about 0.001 % to about 0.1 % based on the total weight of said composition.
24. An aqueous antimicrobial composition, comprising: (a) a physiologically acceptable pH controlling agent; (b) an effective amount of an antimicrobial agent comprising carrageenans which are lambda carrageenan in an amount of at least about 50% by
- 30 dry weight of said carrageenans, remainder of said carrageenans being at least one non-lambda carrageenan; and (c) a lignosulfonic acid.

25. The antimicrobial composition of claim 24, wherein said lignosulfonic acid is present in an amount of about 0.1 % to about 5 % based on the total weight of said composition.
26. The antimicrobial composition of claim 24, further comprising a whitening agent.
- 5 27. The antimicrobial composition of claim 26, wherein the whitening agent comprises titanium dioxide.
28. An aqueous antimicrobial composition, comprising: (a) a physiologically acceptable pH controlling agent; (b) an effective amount of an antimicrobial agent comprising carrageenans which are lambda carrageenan in an amount of at least about 50% by dry weight of said carrageenans, remainder of said carrageenans being at least one non-lambda carrageenan; and (c) a contraceptive agent.
- 10 29. The antimicrobial composition of claim 28, wherein said contraceptive agent comprises a steroid hormone.
30. The antimicrobial composition of claim 28, wherein said contraceptive agent comprises 16-methylene- 17 α -acetoxy- 19-norpregn-4-ene-3, 20-dione.
- 15 31. The antimicrobial composition of claim 28, wherein said contraceptive agent comprises levonorgestrel.
32. An aqueous, antimicrobial composition useful for female hormone replacement therapy, comprising: (a) an effective amount of a female hormone replacement agent; (b) an effective amount of an antimicrobial agent comprising carrageenans which are lambda carrageenan in an amount of at least about 50% by dry weight of said carrageenans, remainder of said carrageenans being at least one non-lambda carrageenan; and (c) a physiologically acceptable pH controlling agent.
- 20 33. A method of inhibiting contraction of a sexually transmitted infection (STI), comprising administering the composition of claim 1 to a human.
- 25 34. The method of claim 33, wherein the composition is administered prior to sexual activity.
35. The method of claim 33, wherein the composition is administered after sexual activity.
- 30 36. The method of claim 33, wherein the composition is administered in the form of a gel, cream, foam, film, or a suppository.

37. The method of claim 33, wherein the composition is administered in the form of a gel.
38. The method of claim 33, wherein said antimicrobial agent comprises about 85% lambda carrageenan and about 15% kappa-II carrageenan, each based on dry weight of said carrageenans, and wherein said antimicrobial agent is present in an amount of about 3 % of said composition.
- 5 39. A method of inhibiting transmission of microbes to a human during sexual activity, comprising administering the composition of claim 1 to a human.
40. The method of claim 39, wherein the microbes comprise HIV.
41. The method of claim 39, wherein the microbes comprise HSV-2.
- 10 42. The method of claim 39, wherein the microbes comprise HSV-1.
43. The method of claim 39, wherein the microbes comprise HPV.
44. The method of claim 39, wherein the microbes comprise *Neisseria gonorrhoeae*.
45. A method of inhibiting contraction of a sexually transmitted infection (STI), comprising administering to a human the composition of claim 1, 18, 19 or 24.
- 15 46. A method of contraception, comprising administering to a female the composition of claim 28.
47. A method of hormone replacement therapy, comprising administering to a female the composition of claim 32.
48. A process for making a metal carrageenate comprising precipitating carrageenan comprising a lambda carrageenan in alcohol, soaking said precipitated carrageenan in a solution containing a metal salt, alcohol and water, separating the metal carrageenate from the solution, washing and drying.
- 20 49. The process of claim 48, wherein the metal is zinc.
50. The process of claim 49, wherein said solution contains 50:50 alcohol:water and 2.5% zinc salt.
- 25 51. The process of claim 49, wherein said soaking step is repeated at least once.
52. An aqueous antimicrobial composition, comprising: (a) a physiologically acceptable pH controlling agent; and (b) an effective amount of an antimicrobial agent comprising a complex of a lambda carrageenan and an antimicrobial, physiologically acceptable water-soluble cationic metal salt.
- 30

53. An aqueous antimicrobial composition, comprising: (a) a physiologically acceptable pH controlling agent; (b) an effective amount of an antimicrobial agent comprising a lambda carrageenan; and (c) a lignosulfonic acid.
54. An aqueous antimicrobial composition, comprising: (a) a physiologically acceptable pH controlling agent; (b) an effective amount of an antimicrobial agent comprising a lambda carrageenan; and (c) a contraceptive agent.
55. An aqueous antimicrobial composition, comprising: (a) a physiologically acceptable pH controlling agent; (b) an effective amount of an antimicrobial agent comprising a lambda carrageenan; and (c) an agent for hormone replacement therapy.

10





Fig.1



Treatment	PT-PCR +/total	Percentage Positive
PBS	16/22	72%
Methyl Cellulose	7/10	70%
Carrageenan mixture	2/22	9%

Fig. 2




Fig. 3






Fig. 4


Blocking effect of LSA on HIV infection







Efficacy of carrageenan and Zn-carrageenan in preventing plaque formation of HSV-2 in Vero cells. Zn-carrageenan is more effective than carrageenan.

Fig. 6





Comparison of long term activity of Zn-carrageenan compared to Conceptrol and Advantage S at a viral challenge dose of 10^4 or 100% infection dose of HSV-2. Zn-carrageenan remains as active 3 hrs after application as it is 5 minutes after application.






Fig. 10




Fig.11